drugset / Trial / NCT05056935

Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

NCT05056935

Phase 2 Completed 131 enrolled Newsoara Biopharma Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to establish preliminary evidence of the efficacy, safety, and tolerability of LB1148 for the treatment of return of gastrointestinal function and decrease Post-Operative Ileus in subjects undergoing elective bowel resection.

Timeline

Start
2019-07-09
Primary completion
2020-07-22
Completion
2020-08-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 700 ml Oral

Indications